Biomerica to Participate at BTIG Biotech Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Biomerica Inc. (NASDAQ: BMRA) announced participation in the 2022 BTIG Biotechnology Conference on August 8-9 in New York City. The CEO will engage in one-on-one meetings at the event. Biomerica specializes in biomedical technologies, developing diagnostic and therapeutic products for gastrointestinal and inflammatory diseases. Their offerings aim to improve health outcomes while reducing healthcare costs.
Details
News Market Reaction – BMRA
The recorded move for BMRA in the trading session of this news was +0.33%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., June 23, 2022 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that the Company’s CEO will participate at the 2022 BTIG Biotechnology Conference being held in person in New York City on Monday, August 8th and Tuesday August 9th, 2022. The Company’s CEO will also be available for in-person one-on-one meetings at the conference.
About Biomerica NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories, for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
CONTACT INFORMATION
John Nesbett / Jennifer Belodeau
IMS Investor Relations
203.972.9200
jnesbett@institutionalms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.